[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100657359":3},{"organization":4,"outcomesModule":7,"designInfo":35,"detailedDescription":38,"studyPopulation":39,"armGroups":40,"interventions":34,"overallOfficials":47,"centralContacts":52,"locations":34,"responsibleParty":58,"collaborators":34,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":34,"eligibilityCriteria":68,"healthyVolunteers":64,"sex":69,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":34,"studyType":75,"phases":34,"briefSummary":76,"conditions":77,"keywords":81,"overallStatus":87,"whyStopped":34,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":34},{"fullName":5,"class":6},"Assiut University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":34},[9],{"measure":10,"description":11,"timeFrame":12},"Clinical Pregnancy Rate","Proportion of women with intrauterine gestational sac with fetal heartbeat by ultrasound at 6 weeks gestation","6 weeks after embryo transfer",[14,18,22,26,30],{"measure":15,"description":16,"timeFrame":17},"Ongoing pregnancy rate","Ongoing pregnancy with heartbeat \\>12 weeks on ultrasound","12 weeks after embryo transfer",{"measure":19,"description":20,"timeFrame":21},"Number of retrieved oocytes","Mean number of oocytes retrieved at pickup","Periprocedurally, at time of oocyte retrieval, during oocyte pickup procedure",{"measure":23,"description":24,"timeFrame":25},"Number of mature MII oocytes","Mean number of mature MII oocytes","Periprocedurally , at time of oocyte retrieval, Day 0, during oocyte pickup procedure",{"measure":27,"description":28,"timeFrame":29},"Fertilization rate","Fertilized oocytes \u002F MII oocytes","1 day after ICSI",{"measure":31,"description":32,"timeFrame":33},"Premature LH surge","LH \\>=10 IU\u002FL or progesterone \\>=1.0 ng\u002FmL before trigger","Baseline (before hCG trigger)",null,{"allocation":34,"interventionModel":34,"interventionModelDescription":34,"primaryPurpose":34,"observationalModel":36,"timePerspective":37,"maskingInfo":34},"COHORT","PROSPECTIVE","Cetrorelix is used as a GnRH antagonist to prevent premature LH surge during controlled ovarian stimulation for ICSI. This observational study will include women aged less than 35 years with normal ovarian reserve and BMI ≥25 kg\u002Fm² who received either half-dose or conventional-dose cetrorelix as part of routine care. Clinical pregnancy rate and secondary reproductive outcomes will be compared between the two groups.","Women aged less than 35 years with BMI ≥25 kg\u002Fm² and normal ovarian reserve who received either half-dose or conventional-dose cetrorelix as part of routine care during GnRH antagonist ICSI cycles at Assiut University Hospital.",[41,44],{"label":42,"type":34,"description":43,"interventionNames":34},"Half-dose Cetrorelix 0.125 mg","Women who received cetrorelix 0.125 mg daily as part of routine GnRH antagonist protocol.",{"label":45,"type":34,"description":46,"interventionNames":34},"Conventional-dose Cetrorelix 0.25 mg","Women who received cetrorelix 0.25 mg daily as part of routine GnRH antagonist protocol.",[48],{"name":49,"affiliation":50,"role":51},"Mohamed S Abdallah, prof","obstetrics and gynecology Department, Assiut University Hospitals","STUDY_CHAIR",[53],{"name":54,"role":55,"phone":56,"phoneExt":34,"email":57},"Samar A Mohy eldin, Resident","CONTACT","01142926439","samarmohy42@gmail.com",{"type":59,"investigatorFullName":60,"investigatorTitle":61,"investigatorAffiliation":5,"oldNameTitle":34,"oldOrganization":34},"PRINCIPAL_INVESTIGATOR","Samar Ahmed Mohy Eldien","Resident Physician","100657359","half-dose-vs-conventional-dose-cetrorelix-in-icsi-cycles-100657359",false,"NCT07836400","Half-dose vs Conventional-dose Cetrorelix in ICSI Cycles","Half-dose Versus Conventional-dose Cetrorelix in Antagonist ICSI Cycles: Prospective Comparative Cohort Study","Inclusion Criteria:\n\n* \\- Age less than 35 years\n* Normal ovarian responders (AMH ≥1.2 ng\u002FmL and AFC 5-15)\n* Body mass index (BMI) ≥25 kg\u002Fm²\n* Written informed consent\n\nExclusion Criteria:\n\n* \\- Age greater than 35 years\n* Diminished ovarian reserve (AMH \\\u003C1.2 ng\u002FmL or AFC \\\u003C5)\n* Congenital uterine anomalies or significant intrauterine pathology\n* Contraindications to ovarian stimulation or pregnancy\n* Refusal to participate","FEMALE","18 Years","34 Years",{"count":73,"type":74},160,"ESTIMATED","OBSERVATIONAL","This prospective cohort study aims to compare the effectiveness of half-dose (0.125 mg\u002Fday) versus conventional-dose (0.25 mg\u002Fday) cetrorelix in GnRH antagonist ICSI cycles regarding clinical pregnancy rate in women with BMI ≥25 kg\u002Fm².",[78,79,80],"Infertility","Infertility, Female","Anovulation",[82,83,84,85,86],"Half-dose","Cetrorelix","ICSI","GnRH Antagonist","Assiut","NOT_YET_RECRUITING","2026-09-22",{"date":90,"type":91},"2026-09-23","ACTUAL",{"date":93,"type":74},"2026-09-20",{"date":95,"type":74},"2028-03-20",{"name":5,"class":6}]